Good afternoon only to the reporters on last Wednesday’s White House COVID-19 press call who told Dr. Anthony Fauci that he was on mute.
And yes, you read that right: the White House is doing regular COVID-19 press calls again! With Dr. Fauci! Who is now President Biden’s Chief Medical Advisor on COVID-19! And CDC Director Dr. Rochelle Walensky! And chair of Biden’s health equity task force Dr. Marcella Nunez-Smith!
Okay, that’s enough exclamation points. The briefings, which will be held three times a week, provide data-driven updates on the state of the pandemic and allow journalists to ask hard questions of the Biden administration’s response. In addition to the scientific experts, briefings so far have featured White House advisors/COVID-19 coordinators Jeff Zients and Andy Slavitt, who can speak to the more logistical aspects of the administration’s actions.
This is, essentially, what a responsible federal government should have been doing since January 2020. But after a year of the Trump administration’s confusion, lack of coordination, and outright lies, it’s refreshing to watch a White House COVID-19 briefing in which every statement doesn’t need to be rigorously fact-checked in real-time.
Besides the press briefings, here are a couple of moves the Biden team made this week that underscore the new administration’s commitment to better (and more transparent) COVID-19 data:
- Publicly releasing the COVID-19 State Profile Reports: Since last spring, the White House COVID-19 Task Force has regularly compiled detailed reports to help national and state leaders respond to the pandemic. The reports include COVID-19 data for states, counties, and cities, along with specific assessments on where governors and state public health officials should focus their efforts in order to control the virus’ spread. In late December, the data behind these reports were released to the public; here’s a CDD post with more info on that release. Biden’s COVID-19 Task Force has kept the data releases going, and this week, they also shared the PDF reports themselves. What’s more, new White House COVID-19 Data Director Cyrus Shahpar made this release his first Tweet on his new official account—and he thanked public advocates for these data, such as the Center for Public Integrity’s Liz Essley Whyte and COVID Exit Strategy’s Ryan Panchadsaram. The release indicates a new commitment to data transparency that we did not see from Trump’s White House for the majority of his tenure.
- Updating the CDC’s COVID-19 dashboard: The CDC has been building out a COVID-19 tracker since the spring, featuring data on cases, testing, vulnerable populations, and (since December) vaccination. But it got a major upgrade this week: the dashboard now has a curated landing page and a sidebar menu that makes it much easier for users to see all the available data. This dashboard also now includes those State Profile Reports I mentioned above, making it easy for users to find information about their regions. And, under the “Your Community” label, you’ll also find an interactive COVID-19 vulnerability index: select your county, and the map will show you how susceptible you are to the pandemic based on your community’s current infection rate, testing, population demographics, health disparities, and more.
- More lead time for vaccine distribution: Last week, I discussed how unpredictable vaccine shipments from the federal government were making it difficult for states—and by extension, local public health departments and individual providers—to coordinate their dose administration. Biden’s team improved the situation this week by giving states their shipment numbers three weeks in advance. The extended lead time will allow vaccine providers to plan out appointments and coordinate other logistics in order to ensure all doses are used. Both the CDC’s Pfizer and Moderna distribution datasets were most recently updated on January 26, with allocation numbers for January 25 and February 1.
- Stepping up the genomic surveillance: In both of this week’s White House COVID-19 briefings, CDC Director Rochelle Walensky announced that the agency is actively looking for new SARS-CoV-2 variants by working with local and international partners. She gave some specifics in Friday’s briefing: “We are now asking for surveillance from every single state,” she said, requiring states to sequence 750 strains each week. Collaborations with both commercial labs and research universities will take the surveillance to thousands of strains per week. As Sarah Braner wrote earlier in January, such surveillance is key to understanding how prevalent the new—and more contagious—coronavirus strains are in the U.S., as well as to detecting future strains that may become a threat in the coming months.
It looks like the CDC may be on its way to adapting its current dashboard into the Nationwide Pandemic Dashboard that Biden promised in his transition plan. But I, for one, am trying not to get too comfortable. The statements still need to be fact-checked, and the hard questions need to be asked. Biden’s team is making the bare minimum look nice—albeit with a few Zoom glitches.
As I look forward into my coverage of the Biden administration’s COVID-19 response, and its healthcare policies more broadly, I’m thinking about this quote from Chris La Tray in his most recent newsletter issue, “Same as it Ever Was”:
“I’m already sick of all the white liberal people humping each other’s legs every time Biden does something that is simply his damn job. “It’s so nice to have a president that….” Blech. Puke. There is copious lingering accountability to be addressed and Joe goddamn Biden is neck deep in it. We are not going back to anything that resembles the last 40 years of his political career, our only way is forward.”
Our only way is forward. To end this pandemic, to prepare for the next one.
Related posts
- Tips for following COVID-19 trends this winterThe U.S. is heading into our first winter since the end of the federal public health emergency for COVID-19. Those of us still following COVID-19 trends might need to change which data sources we use to track the disease this winter, and how we think about trends.
- Paxlovid will be far more expensive and covered by private insurance in 2024, likely leading to access issuesStarting in 2024, the antiviral drug Paxlovid will be a private—and expensive—treatment for COVID-19. The Department of Health and Human Services (HHS) announced about a week ago that it’s reached a deal with Pfizer, the pharmaceutical company that produces Paxlovid, to “transition” this drug into the commercial market within the next few months. The transition will lead to Paxlovid becoming even less accessible than it is now and will exacerbate health inequities that we’ve seen with this drug.
- How is the CDC tracking the latest round of COVID-19 vaccines?Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
- The CDC has a new wastewater surveillance contract; here’s what this means for public data sourcesThis week, the CDC and life sciences company Verily announced that the agency awarded a five-year wastewater surveillance contract to Verily. The announcement marks a shift in the U.S. sewage monitoring landscape and will impact our public COVID-19 data, with short-term gaps and changing coverage in a couple of sources—but ultimate improvements in the long term.